250B MC company a bit of a stretch? Most likely. Able to generate that value in revenue? Almost certainly, IF both cardioprotection and FTO go for full indications/mass adoption in best case scenarios science wise. (well aware that is a massive IF!)
With the new formulation providing a reset patent runway, early approval via breakthrough drug pathway could have Zantrene earning top dollar for longer.
In the Keytruda chart above, total sales for 9 years adds up to US$79.86B. It’s worth keeping in mind that if a simple 18% royalty was paid out on those figures, 9 year earnings would be US$14.37B. Wonder what the SP would be on a company generating that sort of $$?
250B MC company a bit of a stretch? Most likely. Able to...
-
- There are more pages in this discussion • 3,766 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
-0.020(1.06%) |
Mkt cap ! $317.6M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.89 | $1.86 | $25.61K | 13.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 980 | $1.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 519 | 3 |
View Market Depth
| Last trade - 10.57am 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |